(Q39860629)

English

A multicenter, phase II study of bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma

scientific article published on 25 June 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

A multicenter, phase II study of bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

multicenter clinical trial

0 references

gastroesophageal junction adenocarcinoma

0 references

1 reference

based on heuristic

inferred from title

author name string

Manish A Shah

1

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Derek G Power

2

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Hedy L Kindler

3

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Kyle D Holen

4

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Margaret M Kemeny

5

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

David H Ilson

6

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Laura Tang

7

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Marinela Capanu

8

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

John J Wright

9

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

David P Kelsen

10

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

publication date

25 June 2010

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

29

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

1475-1481

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

https://scigraph.springernature.com/pub.10.1007/s10637-010-9474-7

0 references

Global cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9474-7

21 January 2018

The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9474-7

21 January 2018

Clinical update: proteasome inhibitors in solid tumors

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9474-7

21 January 2018

Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9474-7

21 January 2018

Nuclear factor-kappaB in cancer development and progression

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9474-7

21 January 2018

Proteasome inhibition as a novel therapeutic target in human cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9474-7

21 January 2018

Antitumor effects and drug interactions of the proteasome inhibitor bortezomib (PS341) in gastric cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9474-7

21 January 2018

Cancer of the esophagogastric junction

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9474-7

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9474-7

21 January 2018

Immunohistochemical analysis of pRb2/p130, VEGF, EZH2, p53, p16(INK4A), p27(KIP1), p21(WAF1), Ki-67 expression patterns in gastric cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9474-7

21 January 2018

Nuclear factor-kappaB activation correlates with better prognosis and Akt activation in human gastric cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9474-7

21 January 2018

NF-kappaB activation and potentiation of proinflammatory responses by the Helicobacter pylori CagA protein

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9474-7

21 January 2018

Helicobacter pylori-dependent NF-kappa B activation in newly established Mongolian gerbil gastric cancer cell lines.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9474-7

21 January 2018

A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9474-7

21 January 2018

Phase II trial of bortezomib for patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9474-7

21 January 2018

Targeting the ubiquitin-proteasome pathway in breast cancer therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9474-7

21 January 2018

Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9474-7

21 January 2018

A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9474-7

21 January 2018

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9474-7

21 January 2018

NPI-0052 enhances tumoricidal response to conventional cancer therapy in a colon cancer model.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9474-7

21 January 2018

Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9474-7

21 January 2018

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9474-7

21 January 2018

Superfolding of the partially unfolded core-glycosylated intermediate of human P-glycoprotein into the mature enzyme is promoted by substrate-induced transmembrane domain interactions.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9474-7

21 January 2018

Bortezomib, paclitaxel, and carboplatin as a first-line regimen for patients with metastatic esophageal, gastric, and gastroesophageal cancer: phase II results from the North Central Cancer Treatment Group (N044B).

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9474-7

21 January 2018

PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20574790

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nuclear factor-kappaB p65 is a prognostic indicator in gastric carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20574790

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nuclear factor-kappaB p65 (RelA) transcription factor is constitutively activated in human gastric carcinoma tissue

1 reference

https://pubmed.ncbi.nlm.nih.gov/20574790

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327).

1 reference

https://pubmed.ncbi.nlm.nih.gov/20574790

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/20574790

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC).

1 reference

https://pubmed.ncbi.nlm.nih.gov/20574790

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20574790

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression profiling of colorectal carcinomas using tissue microarrays: cell cycle regulatory proteins p21, p27, and p53 as immunohistochemical prognostic markers in univariate and multivariate analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20574790

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapeutic agents in gastric cancer cell lines.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20574790

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oncogenic pathway combinations predict clinical prognosis in gastric cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20574790

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/20574790

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-010-9474-7

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39860629&oldid=2091660561"